Sentinel Lymph Node Mapping in the Management of Colorectal Cancer: Preliminary Report

Roseano, M; Scaramucci, M; Ciutto, Tiziana; Balani, Alessandro; Turoldo, Angelo; Zanconati, Fabrizio; Liguori, G; Leggeri, A

doi:10.1177/030089160308900413

Cited by 11 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all but seven studies [15, 27, 52, 56, 57, 59, 60], MMs were detected using IHC. Cytokeratin, in particular CK AE‐1, CK AE‐3, and CK20, were generally used to detect OTCs and MMs [7, 24, 37, 54, 58]. Sometimes antibodies against carcinoembryonic antigen (CEA) were also used.…”

Section: Resultsmentioning

confidence: 99%

“…For all studies, the median number and range of SLNs and lymph nodes sampled were, respectively, 2.5 (1.8–6.0) and 15.6 (5.5–29.9). The mean failure rate of SLNM was 10% (0–37%), but in six studies the SLN identification rate was 100% [9, 11, 14, 29, 58, 62].…”

Section: Resultsmentioning

confidence: 99%

“…Two methods were employed for diagnosis of SLN: blue dyes or radiolabeled tracers. Two blue dyes were used: patent blue dye V in Europe by ten medical teams [9, 10, 12, 17, 22, 27, 29, 52, 53, 57, 58, 60] and isosulfan blue 1% (lymphazurin) in North America by nine groups [7, 14–16, 19, 34, 40, 46, 54]. Radioactive technetium labeling was rarely performed [25, 56].…”

Section: Resultsmentioning

confidence: 99%

“…One article was found in the recent literature about SLN [54]. Seven articles were added after reviewing the references of other articles [3,[55][56][57][58][59][60][61]. No additional data from ASCO meetings abstracts (1998 to 2004) were found.…”

Section: Main Characteristics Of the Studiesmentioning

confidence: 99%

“…Most of the studies were concerned with colon cancer and only three with rectal carcinoma [10,13,26]. For 16 studies the data for colon and rectal cancers were pooled [7,9,10,14,15,17,19,22,24,27,38,53,[56][57][58][59]. More than half of the studies used TNM staging [7, 9-11, 13, 14, 19, 25, 26, 29, 34, 38, 40, 56, 60, 62].…”

Section: Main Characteristics Of the Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Is Sentinel Lymph Node Mapping in Colorectal Cancer a Future Prognostic Factor? A Meta‐analysis

et al. 2007

View full text Add to dashboard Cite

The diagnostic value of sentinel lymph node mapping (SLNM) in patients with colorectal cancer (CRC) is controversial. Prognostic factors for CRC must be detected to improve its treatment. A PubMed query (key words: colorectal cancer, sentinel node) provided 182 studies on the sentinel lymph node (SLN) for CRC, the abstracts of which were reviewed. Altogether, 48 studies dealing with the diagnostic value of SLNM were selected from PubMed, and 6 other studies were retrieved from reviews. We compared the diagnostic value of SLNM with that of conventional histopathologic examination. We used the diagnostic accuracy odds ratio (DAOR) method. Because of significant heterogeneity, we chose the random effect model (Der Simonian and Laird). Statistics were performed on 33 studies, including 1794 patients (1201 colon and 332 rectum cancers). The mean SLNM failure rate was 10%. The global sensitivity and specificity of the SLNM were, respectively, 70% and 81%. The pooled DAOR was 10.7 (95% confidence interval 7.0-16.5). That means that a patient whose SLN is invaded has 10.7 times more risk to be node-positive than an SLN-negative patient. Lymphatic mapping appears to be readily applicable to CRC. One of the main reasons for the heterogeneity is the performance of the SLNM by Saha et al., whose data had better sensitivity (90%) than those in other studies. The SLNM technique should be better standardized in future studies. Understanding the cause of false-negative SLNs (9%) is a major issue to resolve before routinely using this technique in CRC management. The prognostic implication of micrometastases found in SLNs requires further evaluation.

show abstract